Invetx is building the world's premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. The Invetx team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts, veterinary scientists and clinicians.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/24/20 | $15,000,000 | Series A |
Anterra Capital WuXi Biologics | undisclosed |
| 09/30/20 | $25,500,000 | Series A |
ABC Laboratories AbCellera Biologics Anterra Capital Casdin Capital Tekla Capital Management WuXi Biologics | undisclosed |
